drugset / Trial / NCT05576974

A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)

NCT05576974 ↗

Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

This is a non-randomized, open-label, single-center, safety and imaging feasibility study of Pegsitacianine, an intraoperative fluorescence imaging agent.

Timeline

Start
2024-04-17
Primary completion
2027-12-31
Completion
2027-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator pegsitacianine Diagnostic / imaging agent 1 mg/kg Other